trending Market Intelligence /marketintelligence/en/news-insights/trending/ZbUxIcGX6_poTD83OMFzOw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J, Bayer's Xarelto gets US nod for expanded use in patients

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

J&J, Bayer's Xarelto gets US nod for expanded use in patients

The U.S. Food and Drug Administration approved the expanded use of Johnson & Johnson and Bayer AG's Xarelto to prevent blood clots in another patient population.

Xarelto can now be used to prevent venous thromboembolism, or VTE, in acutely ill patients who are at the risk of developing blood clot complications but are not at a high risk of bleeding. VTE refers to a blood clot that starts in a vein.

The company said Xarelto can be initiated for such patients during hospitalization and after discharge for a duration of 31 to 39 days.

Xarelto is approved for eight indications, six of which are specifically for treating, preventing and reducing the risk of recurrence of VTE across different patient populations.

Xarelto is marketed outside the U.S. by Germany-based Bayer and in the U.S. by Johnson & Johnson.

In March, the companies agreed to pay about $775 million to settle almost all of the approximately 25,000 lawsuits in the U.S. related to the blockbuster drug where plaintiffs alleged that the medicine caused uncontrollable and irreversible bleeding that led to injuries and even deaths.